The biotechnology sector often rides a rollercoaster of high hopes and sharp setbacks, and few cases illustrate this better than the recent plunge in Exelixis’ stock value following the release of data from its STELLAR-303 trial. Focused on zanzalintinib, an experimental drug for metastatic
As we dive into the complex world of healthcare policy, I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose deep understanding of technology and innovation in the industry, coupled with extensive experience in research and development, offers invaluable insights. Today,
Imagine a world where the brain's fundamental energy processes, long thought to be set in stone, are suddenly redefined by a single discovery that could alter the course of treatment for devastating neurological conditions. Researchers from prestigious institutions have recently unveiled a
The startling reality that over 30% of adults may carry dangerous fat deposits deep within their abdomen or liver, even without visible signs of obesity, has sparked intense discussion in the medical community. This hidden fat, often undetectable through traditional measures like body mass index
In the heart of rural America, where hospital closures have left entire communities without emergency care, a staggering crisis unfolds as over 150 facilities have shuttered their doors since tracking began, compounded by a projected $137 billion reduction in federal healthcare spending over the
In a landscape where healthcare should prioritize patient well-being above all, the Malaysian Medical Association (MMA) has raised a critical alarm about the increasing influence of corporate entities on medical decisions, threatening the ethical foundation of the profession. As articulated by its
